Suheung Capsul (008490) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Suheung Capsul stock KRW 53,070, price KRW 17,690, upside +200.0%, quality 55 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 11,483 KRW – 52,526 KRW · fair‑value band 29,086 KRW – 67,926 KRW · the 17,690 KRW price screens below the 53,070 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Suheung Capsul in your weekly email
Every Wednesday you see whether Suheung Capsul is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Suheung Co., Ltd. engages in produces and sells hard and soft capsules. The company provides solid dosage forms, including hard and soft capsule, tablets, powder, granules; fluidity and concentrated liquids; gummy, sticky and water jellies.
Show moreShow less
It offers medical supplies, such as prescription medicines; over-the-counter drugs comprising antipyretic-analgesics, cold medicine, digestive medicine, liver-treatment medicine, and nutritional supplements; and quasi-drugs, which includes low-content vitamin-cosmetic products, multi-vitamin, toothpaste, effervescent tablet, and chewable tablet.
In addition, it provides its capsules under Embocaps brand name. The company was founded in 1973 and is headquartered in Cheongju-si, South Korea.
Stock analysis
Suheung Capsul (008490) currently trades at 17,690 KRW, while our model-based Fair Value estimate is 53,070 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 70,126 KRW per share, and 24 of the 26 models we run sit above the 17,690 KRW price.
Bear case: the Dividend Discount group reads lowest at 8,246 KRW, and 2 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 29,086 KRW (bear) to 67,926 KRW (bull), the price of 17,690 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Suheung Capsul reported revenue of 722B KRW in FY2025 versus 597B KRW in FY2021, a compound +4.9%/yr. Reported net income was 43.5B KRW in FY2025, compounding −5.1%/yr from FY2021.
Key figures
Market cap 197B KRW (≈ $148M) Micro · P/E ratio 5.0 · P/S ratio 0.26 · EPS (TTM) 3,515 KRW · Dividend yield 2.8% · Net margin 5.1% · Return on equity 8.7% · Return on assets (EBIT) 5.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (medium confidence).
What moves the price
The share trades about 40% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at 200%, 008490 screens cheaper than that median.
Fair Value models
Bear29,086 KRWFair Value 53,070 KRWBull67,926 KRW
Price 17,690 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2,610 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Start year 2020 (pandemic). Over 10 years: +9.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ −3.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.1%
Dividend (yield on the price)2.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.9% vs 5.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 138% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +11.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)8.7% · Above median
Return on assets4.1% · Above median
Net margin (12 months)5.1% · Below median
Operating margin (12 months)10.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)12.0% · Above median
Dividend yield (12 months)2.8% · Above median
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Suheung Capsul Fair Value". https://www.fairvalue-calculator.com/stock/008490
Frequently asked questions
Is Suheung Capsul (008490) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 53,070 KRW versus a price of 17,690 KRW, about +200% upside (undervalued).
What is the fair value of 008490?
Our model-based fair value for Suheung Capsul is 53,070 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 17,690 KRW.
What is the quality score of 008490?
Suheung Capsul has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Suheung Capsul (008490)?
Our model-based price target is the fair value of 53,070 KRW (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 29,086 KRW, optimistic scenario 67,926 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Suheung Capsul stock forecast for 2026?
Our models put fair value at 53,070 KRW, about +200% upside versus a price of 17,690 KRW (undervalued). Cautious scenario 29,086 KRW, optimistic scenario 67,926 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Suheung Capsul (008490)?
Suheung Capsul reported trailing-twelve-month revenue of about 766B KRW (latest available figure, as of Nov 8, 2026).
Does Suheung Capsul pay a dividend?
Suheung Capsul currently shows a dividend yield of 2.83% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Suheung Capsul (008490) and when is the ex-dividend date?
Suheung Capsul pays a dividend of 500.00 KRW per share a year, a dividend yield of 2.8%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 1996. The payout ratio is 14.2% of earnings. Free cash flow covers the dividend 5.32 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Suheung Capsul (008490)?
For today's price to be fair in a discounted-cash-flow model, Suheung Capsul would have to grow free cash flow by +13.8 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.5 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 008490 use?
Our models discount Suheung Capsul at 11.6 %: a base by market capitalisation (micro), damped by beta 0.46, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Suheung Capsul that is +13.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Suheung Capsul (008490) delivered so far?
Over the past 5 years revenue at Suheung Capsul grew +5.5 % a year. The price currently implies free-cash-flow growth of +13.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Suheung Capsul (008490) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Suheung Capsul (+13.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Suheung Capsul (008490)?
The free-cash-flow yield on the price is 15.05 %: that much free cash flow Suheung Capsul produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Suheung Capsul (008490)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Suheung Capsul it is 53,070 KRW per share (as of Nov 8, 2026), against a price of 17,690 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Suheung Capsul stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 008490 trades below its calculated fair value: price 17,690 KRW, fair value 53,070 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 008490?
No. The price is what the market pays today (17,690 KRW); the fair value is what the company's own numbers justify (53,070 KRW). For Suheung Capsul the two are 35,380 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Suheung Capsul worth?
The market values Suheung Capsul at about 197B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 17,690 KRW; our models calculate a fair value of 53,070 KRW per share.
What do the bullish and bearish scenarios say about 008490?
Our models span a range for Suheung Capsul: cautious scenario 29,086 KRW, base 53,070 KRW, optimistic 67,926 KRW per share (as of Nov 8, 2026, price 17,690 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 008490?
Suheung Capsul trades at a price-to-earnings ratio of 5.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 53,070 KRW is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 10.9. Other multiples: P/B 0.4, P/S 0.3, EV/EBITDA 2.8.
How solid is the balance sheet of Suheung Capsul (008490)?
Balance-sheet figures for Suheung Capsul (as of Nov 8, 2026): return on equity 8.7%, debt of 0.29 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 008490 from its 52-week high?
Suheung Capsul trades at 17,690 KRW, about 40% below its 52-week high of 29,496 KRW and 9% above the low of 16,200 KRW (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of 53,070 KRW is for.
Which stocks are comparable to Suheung Capsul?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Suheung Capsul stock attractive at the current price?
The data as of Nov 8, 2026: price 17,690 KRW, calculated fair value 53,070 KRW (+200%), Quality Score 55/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 008490 calculated?
We run Suheung Capsul through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 53,070 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Suheung Capsul currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Suheung Capsul (008490)?
The closing price on Nov 11, 2026 was 17,690 KRW. Our model-based fair value is 53,070 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Suheung Capsul right now?
The price is below even our cautious bear case (29,086 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (29,086 KRW to 67,926 KRW) leaves room in how you read the outcome.
Key figures of Suheung Capsul
How large is the market capitalisation of Suheung Capsul (008490)?
The market capitalisation of Suheung Capsul is 197B KRW (≈ $148M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Suheung Capsul (008490)?
The price-to-sales ratio of Suheung Capsul is 0.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Suheung Capsul (008490)?
Earnings per share at Suheung Capsul are 3,515 KRW (price ÷ EPS = P/E 5.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Suheung Capsul (008490)?
The dividend yield of Suheung Capsul is 2.8% (payout 14.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Suheung Capsul (008490)?
The net margin of Suheung Capsul is 5.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Suheung Capsul (008490)?
The return on equity (ROE) of Suheung Capsul is 8.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Suheung Capsul (008490)?
On an EBIT basis the return on assets of Suheung Capsul is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Suheung Capsul (008490)?
The operating margin of Suheung Capsul is 10.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Suheung Capsul (008490)?
Revenue at Suheung Capsul is growing +12.0% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Suheung Capsul (008490)?
Earnings per share at Suheung Capsul are growing −42.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Suheung Capsul (008490) carry?
The net debt of Suheung Capsul is 385B KRW (fiscal year 2025, ≈ 13.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Suheung Capsul in the live analysis
One click puts Suheung Capsul on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026